title: Debate: at what level of coronary heart disease risk should a statin be prescribed?
abstract: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are effective treatments for the primary and secondary prevention of coronary heart disease, but an outstanding issue is determining who should have such treatment. The benefit from treatment with statins appears to be proportional to the underlying risk of coronary heart disease and independent of the factors increasing risk. Most benefit will therefore be achieved by treating people at increased risk of coronary heart disease. Statins reduce coronary morbidity even when the risk of coronary heart disease is relatively low (6% over 10 years), but reduction in all-cause mortality, the true measure of safety has been shown only when the risk of a major coronary heart disease event is 15% over 10 years or greater. At this level of risk patients appear willing to take treatment to gain the benefit expected from statin treatment, and the cost effectiveness of statin treatment is within the range accepted for other treatments. The major impediments to the systematic introduction of statin treatment at this level of risk are the very high overall cost and the large workload in countries like Britain, where the population risk of coronary heart disease is high. For this reason, recent British guidelines correctly advise statin treatment for secondary prevention and primary prevention when the 10 year coronary heart disease risk is 30% or greater as the first priority, moving to a lower coronary heart disease threshold for primary prevention only when resources permit.
authors.affiliation: Section of Clinical Pharmacology and Therapeutics, Royal Hallamshire Hospital, Sheffield, UK. peter.r.jackson@shef.ac.uk
authors.forename: P R
authors.initials: PR
authors.lastname: Jackson
authors.forename: L E
authors.initials: LE
authors.lastname: Ramsay
mesh_terms: D003327:Coronary Disease / Q000188:drug therapy* / Q000401:mortality / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D006801:Humans; D000960:Hypolipidemic Agents / Q000191:economics / Q000627:therapeutic use*; D012307:Risk Factors; D013997:Time Factors; D006113:United Kingdom; D014652:Vascular Diseases / Q000517:prevention & control
chemical_list: D000960:Hypolipidemic Agents